Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?

被引：4
作者：
Dicembrini, Ilaria [1 ]
Mannucci, Edoardo [1 ]
机构：
[1] Careggi Teaching Hosp, Diabetol, Florence, Italy
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2015年 / 184卷
关键词：
Type; 2; diabetes; Myocardial infarction; Dipeptidyl Peptidase 4 inhibitors; METAANALYSIS;
D O I：
10.1016/j.ijcard.2015.02.034
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：543 / 544
页数：2
相关论文
共 50 条
  • [41] Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
    Dai, Yao
    Dai, Dongsheng
    Mercanti, Federico
    Ding, Zufeng
    Wang, Xianwei
    Mehta, Jawahar L.
    ACTA DIABETOLOGICA, 2013, 50 (06) : 827 - 835
  • [42] The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
    Green, Jennifer B.
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 54 - 61
  • [43] Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis
    Radel, Joshua A.
    Pender, Danielle N.
    Shah, Sachin A.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (07) : 697 - 704
  • [44] Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin
    Capuano, Annalisa
    Sportiello, Liberata
    Maiorino, Maria Ida
    Rossi, Francesco
    Giugliano, Dario
    Esposito, Katherine
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 989 - 1001
  • [45] Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences
    Singh, Awadhesh Kumar
    Singh, Ritu
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (04) : 605 - 616
  • [46] The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study
    Gamble, John-Michael
    Donnan, Jennifer R.
    Chibrikov, Eugene
    Twells, Laurie K.
    Midodzi, William K.
    Majumdar, Sumit R.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 136 : 159 - 167
  • [47] Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials
    Mosenzon, Ofri
    Raz, Itamar
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2012, 14 (0B) : B22 - B29
  • [48] Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
    Kongwatcharapong, J.
    Dilokthornsakul, P.
    Nathisuwan, S.
    Phrommintikul, A.
    Chaiyakunapruk, N.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 211 : 88 - 95
  • [49] Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study
    Kim, N. H.
    Choi, J.
    Choi, K. M.
    Baik, S. H.
    Lee, J.
    Kim, S. G.
    DIABETES & METABOLISM, 2018, 44 (04) : 361 - 367
  • [50] Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
    Wang, Xia
    Zheng, Peilin
    Huang, Gan
    Yang, Lin
    Zhou, Zhiguang
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (04) : 473 - 480
12345